Business
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
Revolutionary Oral Interferon Technology Combines Unmatched Advantages and Global Potential in the $16 Billion Coronavirus Market SAN DIEGO, CA / ACCESS
About this update from Ainos, Inc.
[{"type":"text","content":"Revolutionary Oral Interferon Technology Combines Unmatched Advantages and Global Potential in the $16 Billion Coronavirus Market SAN DIEGO, CA / ACCESS Newswire / January 27, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (\"Ainos\" or the \"Company\") proudly announces the granting of a pivotal invention patent in Japan (Patent No. 7619659) for its groundbreaking oral interferon formulation, VELDONA®, to treat and prevent coronavirus infections. Following the recent patent approval in Taiwan, this Japanese patent strengthens Ainos' global intellectual property (IP) portfolio and establishes the Company as a leader in differentiated antiviral solutions.The global coronavirus therapeutics market is projected to exceed $16 billion by 2031. With its patented sublingual interferon technology, Ainos is poised to redefine antiviral treatment standards, offering a cost-effective, scalable, and patient-friendly alternative to traditional therapies.Key Patent Highlights and Technical InnovationsThe newly granted patent includes 15 key claims that deliver comprehensive protection for VELDONA®, covering its formulation, novel sublingual and buccal delivery mechanisms, and broad therapeutic applications. The patented features emphasize:• Low-Dose Administration: Using doses under 1,000 IU to optimize efficacy and minimize side effects.• Innovative Delivery Mechanisms: Sublingual and buccal absorption for rapid action and enhanced bioavailability, eliminating the need for injections.• Flexible Dosage Forms: Includes lozenges, tablets, films, and sprays, offering greater convenience for patients.• No Cold Chain Requirements: Unlike traditional interferon therapies that rely on costly cold chain logistics, VELDONA®'s oral formulation significantly reduces logistical and operational costs.\"This patent represents a significant breakthrough for interferon-based therapies. With patents already granted in Taiwan and Japan, and additional applications underway in other countries, we are reinforcing our global IP portfolio and advancing our commercialization strategy in a multi-billion-dollar market,\" said Chun-Hsien (Eddy) Tsai, Chairman and CEO of Ainos.A Differentiated Solution for a Persistent ChallengeAs coronavirus continues to mutate and pose long-term threats to global health, VELDONA® offers dual benefits:1. Treatment: Proven broad-spectr...